Open Access

REVIEW

The role of LIN28B in tumor progression and metastasis in solid tumor entities

TABEA GEWALT^1,2, KA-WON NOH³, LYDIA MEDER^1,2,4,*

1 Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
2 Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany
3 Institute for Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
4 Mildred Scheel School of Oncology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

* Corresponding Author: LYDIA MEDER. Email:

Oncology Research 2023, 31(2), 101-115. https://doi.org/10.32604/or.2023.028105

Received 30 November 2022; Accepted 16 February 2023; Issue published 10 April 2023

Abstract

LIN28B is an RNA-binding protein that targets a broad range of microRNAs and modulates their maturation and activity. Under normal conditions, LIN28B is exclusively expressed in embryogenic stem cells, blocking differentiation and promoting proliferation. In addition, it can play a role in epithelial-to-mesenchymal transition by repressing the biogenesis of let-7 microRNAs. In malignancies, LIN28B is frequently overexpressed, which is associated with increased tumor aggressiveness and metastatic properties. In this review, we discuss the molecular mechanisms of LIN28B in promoting tumor progression and metastasis in solid tumor entities and its potential use as a clinical therapeutic target and biomarker.

---

Keywords

---